Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.

Claims

37 · 2 independent · depth 4

37 granted claims

›1.independentA compound of formula (I):+19

›2.↳ 1The compound according to claim 1, wherein one of R3 and R4 is C1-C8 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.d2+1

›4.↳ 1The compound according to claim 1, wherein X1 and X2 are, independently, hydrogen, hydroxy, chloro or fluoro.d2

›5.↳ 1The compound according to claim 1, wherein one of R3 and R4 is C1-C8 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein R1 and R2 are, i…d2+1

›7.↳ 1The compound according to claim 1, wherein one of R3 and R4 is aryl or heteroaryl.d2+4

›12.↳ 1The compound according to claim 1, wherein X1 is hydroxy and X2 is hydrogen.d2

›13.↳ 1The compound according to claim 1, wherein a hydroxy is at the 1-position.d2

›14.↳ 1The compound according to claim 1, wherein a hydrogen is at the 1-position.d2

›15.↳ 1The compound according to claim 1 having a formula of:d2

›16.↳ 1The compound according to claim 1, wherein R1 and R2 are, independently, hydrogen or methyl; R3 is hydrogen, R4 is phenyl; X1 and X2 are hydrogen.d2

›32.↳ 1A composition comprising a compound according to claim 1 and a carrier.d2+1

›36.↳ 1A method of treating a disease in a subject comprising:nadministering to a subject an effective amount of a compound according to claim 1;wherein the …d2+1

›17.independentA compound of formula (II):+16

›18.↳ 17The compound according to claim 17, wherein one of R3, R4 and R5 is Cr C5 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl.d2+1

›20.↳ 17The compound according to claim 17, wherein X1 and X2 are, independently, hydrogen, hydroxy, chloro or fluoro.d2

›21.↳ 17The compound according to claim 17, wherein one of R3, R4 and R5 is C1-C8 alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein R1 and R2 a…d2+1

›23.↳ 17The compound according to claim 17, wherein one of R3, R4 and R5 is aryl or heteroaryl.d2+4

›28.↳ 17The compound according to claim 17, wherein X1 is hydroxy and X2 is hydrogen.d2

›29.↳ 17The compound according to claim 17, wherein a hydroxy is at the 1-position.d2

›30.↳ 17The compound according to claim 17, wherein a hydrogen is at the 1-position.d2

›31.↳ 17The compound according to claim 17, wherein R1 and R2 are, independently, hydrogen or methyl; R3 and R4 are hydrogen, R5 is phenyl; X1 and X2 are hydr…d2

›34.↳ 17A composition comprising a compound according to claim 17 and a carrier.d2+1

Classifications

4 codes

IPC · International Patent Classification

Section A — Human necessities

A61K31/47

Section C — Chemistry; metallurgy

C07D401/02

USPC · US Patent Classification

514/310546/143

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

3.7 y

1,355 days filing → grant

Office actions

after a restriction

Responses

1 RCE

Interviews

examiner interview summaries

Examiner

Zinna Northington Davis

art unit 1625 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 155 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20100022585 A1	28 Jan 2010

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.